Zydus Cadila granted approval from US FDA to market antipsychotic drug
Category: #health  By Pankaj Singh  Date: 2019-01-09
  • share
  • Twitter
  • Facebook
  • LinkedIn

Zydus Cadila granted approval from US FDA to market antipsychotic drug

Indian pharmaceutical firm Zydus Cadila has recently announced that the company has received final approval from the health regulator of the U.S. for marketing Aripiprazole tablets, an antipsychotic drug.

The company said in a BSE Filing that the United States Food and Drug Administration (USFDA) has granted an approval to market the drug in the strengths of 2 mg, 5 mg, 10 mg, 15 mg, 20 mg, and 30 mg.

Zydus Cadila further said that the drug would be manufactured at the formulations manufacturing facility of the group at Moraiya, Ahmedabad.

The antipsychotic drug (atypical type), Aripiprazole, is allegedly used in treating mood/mental disorders, for instance, Tourette's disorder, schizophrenia, bipolar disorder as well as irritability associated with autistic disorder. The drug is utilized in combination with various medications for treating depression. It would also work by assisting in restoring the balance of specific natural chemicals in the brain (neurotransmitters).

Since the group has started filing abbreviated new drug applications (ANDAs) in 2003-04, it has been seemingly granted over 243 approvals, and has filed more than 330 ANDAs since then.

For the record, the leading pharma company Zydus Cadila is a global, fully integrated healthcare provider. The company has strong capabilities with in-depth domain expertise in the healthcare field across the spectrum of the pharmaceutical value chain. From active pharmaceutical ingredients to formulations and wellness products to animal healthcare products, the company has built a reputation amongst Indian pharmaceutical corporations for delivering complete and comprehensive healthcare solutions.

Following its brand promise to be dedicated to life in all the dimensions, Zydus Cadila purportedly keeps on innovating with an unswerving focus for addressing the healthcare needs that are unmet. The company also simultaneously rededicates itself towards its mission to create healthier, happier communities around the world.



About Author

Pankaj Singh

Email: [email protected]   

Pankaj Singh

Pankaj Singh Develops content for Market Size Forecasters, Algosonline, and a couple of other platforms. A Post Graduate in Management by qualification, he worked as an underwriter in the UK insurance domain before deciding to switch his field of profession. With exp...

Read More

More News By Pankaj Singh

Epizyme gets FDA approval for TAZVERIK™ to treat epithelioid sarcoma
Epizyme gets FDA approval for TAZVERIK™ to treat epithelioid sarcoma
By Pankaj Singh

Epizyme, Inc., a renowned biopharmaceutical company developing new epigenetic therapies, has reportedly announced that the United States Food and Drug Administration has granted the accelerated approval of the company&...

PayPal and UnionPay partner to expand their global consumer base
PayPal and UnionPay partner to expand their global consumer base
By Pankaj Singh

Digital payment applications have simplified cashless transactions by offering payment options in both offline and online mode. Within a short span of time, the digital payment industry has seen significant growth, wit...

Eli Lilly and Company to build a manufacturing unit in North Carolina
Eli Lilly and Company to build a manufacturing unit in North Carolina
By Pankaj Singh

Global pharmaceutical firm, Eli Lilly and Company has recently revealed plans to create over 460 new jobs by investing nearly $470 million in Durham, North Carolina. Reportedly, the project would introduce a brand new ...